TCTMD covers new data on two next-generation drugs, retatrutide and survodutide, for weight loss in diabetic patients. Tap through for the trial details.
Recap by typeshit. Full story at TCTMD.com.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
He says this has gone on for around two years, meaning many people are taking a drug at scale before it has even reached the market.
A quick reaction clip from obesity medicine doctor Spencer Nadolsky responding to a joke about GLP-1 drugs. Light content with no new information.
Loading…